New Haven-based Vion Pharmaceuticals has ceased enrolling and treating patients in a late stage clinical trial for its leukemia drug after an independent review board said the mortality rate of patients in the study was too high, the company reported. The drug, Cloretazine, was being tested to treat patients with a relapse of adult myelogenous leukemia. The decision to halt enrollment was based on clinical date from the first 210 patients treated.
Get our email newsletter
Stay up-to-date on the companies, people and issues that impact businesses in Central Massachusetts.
